Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01642732 · ClinicalTrials.gov registry record · Phase 1
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01642732: Clinical Trial Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
NCT01642732 is a Phase 1 study that was terminated before completion, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01642732, a Phase 1 study, was terminated before completion, sponsored by University of Michigan Rogel Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purposes of this study are to: * Determine the safest and highest dose of the study drug RAD001 (Everolimus) that can be taken in combination with hormonal and radiation therapy in men with high risk prostate cancer. * Evaluate changes in patient reported quality of life * Evaluate biomarkers from prostate tumor samples. Biomarkers are various traits which can be used to identify the progress of a disease or condition, which can help researchers determine the effect the study treatment has on the tumor. Biomarkers can also help determine areas for further research.
Interventions
- OTHER Everolimus, lupron, bicalutamide, and radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2012-10 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Why NCT01642732 stopped before completion
NCT01642732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Everolimus, lupron, bicalutamide, and radiation is the first listed.
NCT01642732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01642732 about?
NCT01642732 is a clinical study titled "Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer". The purposes of this study are to: * Determine the safest and highest dose of the study drug RAD001 (Everolimus) that can be taken in combination with hormonal and radiation therapy in men with high risk prostate cancer. * Evaluate changes in patient reported quality of life * Evaluate biomarkers f...
What is the current status of trial NCT01642732?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2012-10. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01642732?
The interventions under investigation include: Everolimus, lupron, bicalutamide, and radiation (OTHER).
Who is sponsoring clinical trial NCT01642732?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01642732's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia